Lakefront Biotherapeutics valuation
€30.38Change from previous close: −1.62%Absolute change: −€0.50
Valuation
The P/E ratio is 2.53. The average price target of 7 analysts is €32.61.
Data as of November 22, 2026
Lakefront Biotherapeutics compared with similar companies
Lakefront Biotherapeutics's P/E (trailing 12 months): 2.53, −83% against the median of a group of 9 similar companies (14.7).
| Metric | Lakefront Biotherapeutics | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 2.53 | 14.7 | 6.16 – 38.0 | Low |
| Price/book | 0.61 | 3.62 | 1.52 – 8.03 | Low |
| Price/sales | 2.01 | 4.08 | 2.56 – 11.5 | Low |
| Gross margin | 67.6% | 87.2% | 58.9% – 93.2% | Middle |
| Operating margin | 57.5% | 21.3% | 15.4% – 43.5% | High |
| Net margin | 60.2% | 24.3% | 8.4% – 45.1% | High |
| ROE | 20.1% | 16.6% | 10.5% – 27.7% | Middle |
| Debt/equity | 0.00 | 0.03 | 0.02 – 0.34 | Low |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Other metrics
Valuation multiples
- Market cap
- €1.99B
- Enterprise value
- -€238.58M
- Forward P/E
- -10.9
- EV/EBITDA
- -0.42
- EV/revenue
- -0.24
Profitability and growth
- ROA
- 9.9%
- ROIC
- 12.0%
- Revenue growth (year over year)
- -81.5%
- Earnings growth (year over year)
- -101.9%
Financial health
- Total cash
- €2.24B
- Total debt
- €6.36M
- Current ratio
- 32.8
- Quick ratio
- 32.6
- Altman Z-Score
- 13.9
- Piotroski F-Score
- 5.00
Dividends
- Dividend yield
- 0.0%
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- €32.61
- Median price target
- €36.00
- High price target
- €44.80
- Low price target
- €19.00
- Analysts with a price target
- 7
- Consensus
- Hold
- Forward EPS
- -€2.78
- EPS estimate, current year
- -€1.83
Shares and trading
- Beta
- 0.01
- Average volume
- 92.59K
- Shares outstanding
- 65.48M
- Float
- 23.02M
- Institutional ownership
- 43.6%
- Insider ownership
- 25.4%
